NeOnc reports Q2 2026 net loss of $14.2M; confirms Aug 12 Phase 2a NEO100 topline data

NEONC TECHNOLOGIES HOLDINGS, INC.

2026-Q2 EPS reported -$0.96

Net loss $14.2M ($0.58/sh) vs $5.7M ($0.30/sh) in Q2 2025; R&D up to $2.6M from $0.7M.
Cash $2.0M at 6/30/26; undrawn $10M HCWG credit line; $44.5M available under Mast Hill facility.
Received UAE IND approvals for NEO100 (covering all programs) and NEO212 (Phase 2) in June 2026.
FDA written feedback on NEO212 CMC and tablet formulation received July 2026; official minutes expected Aug 2026.
Phase 2a NEO100 topline results to be presented Aug 12, 2026; Nasim Shomali appointed to board effective July 1, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.